Prosecution Insights
Last updated: April 19, 2026
Application No. 17/782,482

Modular system for a drug delivery device with electronic and corresponding modules and method

Non-Final OA §103
Filed
Jun 03, 2022
Examiner
AHMED, TASNIM M
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sanofi
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
86%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
342 granted / 427 resolved
+10.1% vs TC avg
Moderate +6% lift
Without
With
+6.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
32 currently pending
Career history
459
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
29.9%
-10.1% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 427 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group II (claims 39-49) in the reply filed on 29 July 2025 is acknowledged. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Drawings The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they include the following reference character(s) not mentioned in the description: 902 (Fig. 9). Corrected drawing sheets in compliance with 37 CFR 1.121(d), or amendment to the specification to add the reference character(s) in the description in compliance with 37 CFR 1.121(b) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 39 and 49 are rejected under 35 U.S.C. 103 as being unpatentable over Byerly et al (US 2020/0171246) in view of Liskow (US 2018/0352666). Regarding claim 39, Byerly discloses: An electronic module (80; Fig. 5) comprising: a detector unit (84) for detecting an amount of a drug arranged for delivery (¶0061); an electronic unit (76) operatively coupled to the detector unit (84) (¶0045), wherein the electronic module (80) is configured to be removably coupled to a proximal end region of a mechanical module (14; Fig. 2); a substrate (116; Fig. 7) that carries a part of the electronic unit (76), a chassis (90) comprising a part of the detector unit (84) and an electrical sensor (110). Byerly is silent regarding “wherein one or more sides of the substrate is covered at least partially by a potting compound” and the chassis is “configured to separate the potting compound from” the electrical sensor. However, Liskow teaches an electronics module of a device (Fig. 5), thus being in the same field of endeavor, that uses a potting compound (7) on one side of a circuit board (2) to form a fluid-tight seal to protect the electronics of the device (¶0069). As applied to Byerly, the body wall (115) of the chassis (90) would physically separate the potting compound from the sensor (110). It would have been obvious to a person of ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the device of Byerly to incorporate a potting compound as taught by Liskow in order to protect the electronics of the device, as recognized by Liskow. Regarding claim 49, Byerly in view of Liskow discloses: The electronic module according to claim 39, wherein the electronic module (80) comprises: a module part (98; Fig. 6) comprising at least one side wall (102), and one or more of an electrical power source (¶0045 – coin cell battery) carried by the module part or by a mechanical carrier (115), a delivery button (92) comprising a delivery surface configured to be pressed to initiate a delivery of a drug from a drug delivery device (¶0063), the delivery button (92) carried by the module part or by the mechanical carrier (115), and a lateral setting surface (90) configured to set a dose of the drug for delivery (¶0061). Allowable Subject Matter Claims 40-48 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TASNIM M AHMED whose telephone number is (571)272-9536. The examiner can normally be reached M-F 9am-5pm Pacific time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bhisma Mehta can be reached at (571)272-3383. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TASNIM MEHJABIN AHMED/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jun 03, 2022
Application Filed
Nov 29, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599722
SYRINGE HOLDER
2y 5m to grant Granted Apr 14, 2026
Patent 12599727
Syringe with Suction-Based Automatic Disabling
2y 5m to grant Granted Apr 14, 2026
Patent 12594383
LOCK MECHANISM FOR A MEDICAMENT DELIVERY DEVICE
2y 5m to grant Granted Apr 07, 2026
Patent 12594380
Medication Injector Assembly And Method Of Use
2y 5m to grant Granted Apr 07, 2026
Patent 12564689
INJECTION DEVICE AND COMPONENTS THEREOF
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
86%
With Interview (+6.4%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 427 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month